| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.1M | — | +182.3% |
| Cost of Revenue | $792K | — | +166.0% |
| R&D Expense | $476K | — | -3.8% |
| SG&A Expense | $1.8M | — | +10.0% |
| Operating Income | -$1.9M | — | +5.0% |
| Income Tax | $0 | — | — |
| Net Income | -$2.0M | — | +3.6% |
| EPS (Basic) | -$0.05 | — | +28.6% |
| EPS (Diluted) | -$0.05 | — | +28.6% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $4.2M | -8.1% | -16.1% |
| Short-term Investments | $1.4M | -49.6% | -41.0% |
| Accounts Receivable | $996K | -8.6% | +349.4% |
| Current Assets | $7.7M | -22.2% | -1.3% |
| Total Assets | $7.8M | -21.5% | -1.1% |
| Current Liabilities | $3.2M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$2.0M | — | -0.7% |
| Investing Cash Flow | $1.3M | — | +162.6% |
| Financing Cash Flow | $24K | — | +0.0% |
| +62.3% |
| Total Liabilities | $8.2M | -5.7% | +17.9% |
| Stockholders' Equity | -$408K | -133.1% | -144.1% |